Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: Results in three additional patients

Michael P. Whyte, William H. McAlister, Lance S. Patton, H. Lynn Magill, Michael D. Fallon, William B. Lorentz, Henry G. Herrod

Research output: Contribution to journalArticlepeer-review

75 Scopus citations

Abstract

After biochemical and radiographic studies, enzyme replacement therapy in three patients with the infantile form of hypophosphatasia was attempted by weekly intravenous infusions of bone alkaline phosphatase-rich (BAP) plasma from patients with Paget bone disease. Subsequently, circulating BAP activity was substantially increased in each patient, and in one was maintained in the normal range for nearly 2 months. Despite partial or complete correction of the deficiency of circulating BAP activity, we observed no radiographic evidence for arrest of progressive osteopenia or improvement in rachitic defects in any of the patients. Failure of infants with hypophosphatasia to show significant healing of rickets on correction of circulating BAP activity supports the hypothesis that this isoenzyme functions in situ during normal skeletal mineralization.

Original languageEnglish
Pages (from-to)926-933
Number of pages8
JournalThe Journal of Pediatrics
Volume105
Issue number6
DOIs
StatePublished - Dec 1984

Fingerprint

Dive into the research topics of 'Enzyme replacement therapy for infantile hypophosphatasia attempted by intravenous infusions of alkaline phosphatase-rich Paget plasma: Results in three additional patients'. Together they form a unique fingerprint.

Cite this